Source: International Congress 2017 – MDRTB: detection and management
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Borisov (Moscow, Russian Federation). Bedaquiline-containing regimens for chronic XDR-TB patients: up to 120 weeks after initiation. 3487

Member's Comments

No comment yet.

Related content which might interest you: Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Patterns of drug resistance at initiation of re-treatment across relapse, default and failure subcategories in previously treated tubercular patients Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice Source: Eur Respir J, 53 (2) 1801128; 10.1183/13993003.01128-2018 Year: 2019 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 Managing tuberculosis in chronic kidney disease: An evaluation of patient treatment regimens Source: Annual Congress 2011 - Tuberculosis in special populations Year: 2011 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 Retreatment of tuberculosis patients after the treatment interruption Source: Eur Respir J 2006; 28: Suppl. 50, 506s Year: 2006 Drug resistance pattern of directly observed treatment shortcourse (DOTS) category-II relapse patients Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011 Linezolide in complex treatment of XDR-TB patients Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Experience of Bedaquiline use in treatment of XDR-TB patients Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017